| 体内研究: |
GNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%. GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo. GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice. Pharmacokinetic Parameters of GNF2133 in CD-1 mice. |
| 参考文献: |
1. Liu YA, et al. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. J Med Chem. 2020 Mar 26;63(6):2958-2973. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.301 ml |
11.507 ml |
23.013 ml |
| 5 mM |
0.46 ml |
2.301 ml |
4.603 ml |
| 10 mM |
0.23 ml |
1.151 ml |
2.301 ml |
| 50 mM |
0.046 ml |
0.23 ml |
0.46 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |